{"analyses":[{"ciLowerLimit":"0.362","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.699","estimateComment":"HR is from the Cox proportional hazards model","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5121","paramType":"Hazard Ratio (HR)","paramValue":"0.784","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.6","upperLimit":"50.9","value":"30.6"},{"comment":"Upper limit could not be estimated due to insufficient number of events","groupId":"OG001","lowerLimit":"10.9","upperLimit":"NA","value":"18.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Duration of RBC-TI was defined as the longest duration of response for participants who achieved RBC-TI of ≥ 8 weeks during the treatment period Week 1 through Week 48. Participants who maintained RBC-TI through the end of the treatment period were censored at the date of IP discontinuation or death, whichever occurred first. Median was estimated from unstratified Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Luspatercept 1.0 mg/Kg SC on Day 1 of each 21-day treatment cycle","id":"OG000","title":"Luspatercept"},{"description":"Placebo (Volume equivalent to experimental arm) SC on Day 1 of each 21-day treatment cycle","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"All treated participants who achieved RBC-TI ≥ 8 weeks during Week 1 through Week 48 of study treatment","reportingStatus":"POSTED","timeFrame":"From start of study treatment to 16 weeks after last dose, up to approximately 93 weeks","title":"Duration of Red Blood Cell Transfusion Independence (RBC-TI) - Week 1 Through Week 48","type":"SECONDARY","unitOfMeasure":"Weeks"}